Teladoc Health (TDOC)
Market Price (12/20/2025): $7.22 | Market Cap: $1.3 BilSector: Health Care | Industry: Health Care Technology
Teladoc Health (TDOC)
Market Price (12/20/2025): $7.22Market Cap: $1.3 BilSector: Health CareIndustry: Health Care Technology
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12% | Weak multi-year price returns2Y Excs Rtn is -110%, 3Y Excs Rtn is -146% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -179 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.1% |
| Attractive yieldFCF Yield is 11% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.4%, Rev Chg QQuarterly Revenue Change % is -2.2% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% | |
| Key risksTDOC key risks include [1] significant underperformance and profitability challenges within its BetterHelp segment and [2] intense competition from large tech and retail entrants threatening its market share. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Attractive yieldFCF Yield is 11% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -110%, 3Y Excs Rtn is -146% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -179 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.1% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.4%, Rev Chg QQuarterly Revenue Change % is -2.2% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% |
| Key risksTDOC key risks include [1] significant underperformance and profitability challenges within its BetterHelp segment and [2] intense competition from large tech and retail entrants threatening its market share. |
Valuation, Metrics & Events
TDOC Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are five key points explaining the movement in Teladoc Health (TDOC) stock from August 31, 2025, to December 20, 2025:
**1. Lower-than-expected Q3 2025 Financial Results and Guidance**
Teladoc Health reported a 2% year-over-year decrease in revenue for the third quarter of 2025, reaching $626.4 million, which was slightly below analyst estimates. The company's GAAP net loss widened to $49.5 million, or $0.28 per share, exceeding consensus expectations. Following this earnings release on October 29, 2025, Teladoc's stock experienced an approximate 2.8% decline in after-market trading. Furthermore, the company narrowed its full-year 2025 revenue guidance, with the midpoint remaining unchanged but falling slightly below prior analyst estimates, contributing to investor caution.
**2. Persistent Weakness in the BetterHelp Segment**
The BetterHelp segment continued to be a drag on overall performance, reporting an 8% decline in revenue during the third quarter of 2025. This segment's adjusted EBITDA also saw a significant drop of 75%. The company anticipates that the BetterHelp segment will continue to face revenue challenges. This ongoing underperformance in a key segment likely contributed to the negative investor sentiment.
**3. Negative Analyst Sentiment and Price Target Revisions**
During the period, several financial analysts maintained "Hold" ratings on TDOC stock, and some adjusted their price targets downwards in October and November 2025. The overall market sentiment for Teladoc Health was described as "Bearish" by some sources, with prevailing "Weak Sentiment" noted as late as December 2025. By mid-November 2025, Teladoc Health's stock had already experienced a year-to-date loss of 23.9%, indicating a sustained negative outlook from the investment community. Analysts also generally favored other "medical" companies over Teladoc Health.
**4. Chief Financial Officer Transition**
Teladoc Health announced on October 23, 2025, that its Chief Financial Officer, Mala Murthy, would be stepping down. While the departure was noted as amicable, a change in top financial leadership can introduce uncertainty for investors regarding the company's financial strategy and future direction, potentially contributing to a negative stock reaction.
**5. Concerns Over Long-term Growth and Valuation**
Analyses published in December 2025 highlighted concerns regarding Teladoc Health's long-term growth prospects. The company's annual revenue growth over the past three years was considered below industry standards for the consumer internet sector, and projected sales for the next 12 months were anticipated to be flat, suggesting a slowdown in demand. Additionally, Teladoc Health faced ongoing financial challenges, including a negative Return on Equity (ROE) and a distressing Altman Z-Score, which indicated potential financial vulnerability and further weighed on investor confidence.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TDOC Return | 139% | -54% | -74% | -9% | -58% | -21% | -91% |
| Peers Return | � | � | -29% | 9% | 38% | 15% | � |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| TDOC Win Rate | 83% | 25% | 25% | 50% | 25% | 33% | |
| Peers Win Rate | � | 37% | 37% | 52% | 57% | 45% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| TDOC Max Drawdown | -1% | -56% | -75% | -34% | -68% | -28% | |
| Peers Max Drawdown | � | � | -45% | -29% | -31% | -18% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: AMWL, HIMS, DOCS, CVS, AMZN. See TDOC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/19/2025 (YTD)
How Low Can It Go
| Event | TDOC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -94.7% | -25.4% |
| % Gain to Breakeven | 1791.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -30.9% | -33.9% |
| % Gain to Breakeven | 44.6% | 51.3% |
| Time to Breakeven | 73 days | 148 days |
| 2018 Correction | ||
| % Loss | -50.3% | -19.8% |
| % Gain to Breakeven | 101.4% | 24.7% |
| Time to Breakeven | 378 days | 120 days |
Compare to
In The Past
Teladoc Health's stock fell -94.7% during the 2022 Inflation Shock from a high on 2/8/2021. A -94.7% loss requires a 1791.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | Date | |
|---|---|---|---|
| DASHBOARDS | |||
| Teladoc Health Earnings Notes | |||
| Can Teladoc Health Stock Recover If Markets Fall? | Return | ||
| Teladoc Health (TDOC) Revenue Comparison | Financials | ||
| Teladoc Health (TDOC) Operating Income Comparison | Financials | ||
| Teladoc Health (TDOC) Net Income Comparison | Financials | ||
| Teladoc Health (TDOC) Debt Comparison | Financials | ||
| Teladoc Health (TDOC) EBITDA Comparison | Financials | ||
| Teladoc Health (TDOC) Operating Cash Flow Comparison | Financials | ||
| Teladoc Health (TDOC) Tax Expense Comparison | Financials | ||
| TDOC Dip Buy Analysis | |||
| ARTICLES | |||
| What’s Next For Teladoc Stock After An 89% Fall In Three Years? | July 7th, 2023 | ||
| Teladoc, CRISPR: Finally Time To Buy Beaten Down Healthcare Names? | June 8th, 2022 | ||
| Down 20% In A Month, Is Teladoc Stock A Buy? | January 25th, 2022 | ||
| Here’s Why Teladoc Stock Looks Attractive At $140 | May 17th, 2021 |
Trade Ideas
Select past ideas related to TDOC. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 17.4% | 17.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.9% | 10.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.4% | 11.4% | -5.1% |
| 04302024 | TDOC | Teladoc Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -30.0% | -43.6% | -48.9% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 17.4% | 17.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.9% | 10.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.4% | 11.4% | -5.1% |
| 04302024 | TDOC | Teladoc Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -30.0% | -43.6% | -48.9% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Teladoc Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 39.61 |
| Mkt Cap | 8.1 |
| Rev LTM | 2,370 |
| Op Inc LTM | 181 |
| FCF LTM | 226 |
| FCF 3Y Avg | 191 |
| CFO LTM | 322 |
| CFO 3Y Avg | 271 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.8% |
| Rev Chg 3Y Avg | 9.5% |
| Rev Chg Q | 10.6% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Mgn LTM | 4.0% |
| Op Mgn 3Y Avg | 2.2% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 13.1% |
| CFO/Rev 3Y Avg | 11.8% |
| FCF/Rev LTM | 3.7% |
| FCF/Rev 3Y Avg | 4.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 8.1 |
| P/S | 2.1 |
| P/EBIT | 22.4 |
| P/E | 33.3 |
| P/CFO | 15.4 |
| Total Yield | 2.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.6% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.8% |
| 3M Rtn | -18.2% |
| 6M Rtn | -9.6% |
| 12M Rtn | -8.8% |
| 3Y Rtn | 8.3% |
| 1M Excs Rtn | -1.1% |
| 3M Excs Rtn | -22.1% |
| 6M Excs Rtn | -25.3% |
| 12M Excs Rtn | -22.4% |
| 3Y Excs Rtn | -67.7% |
Comparison Analyses
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Integrated Care | 1,469 | 1,374 | 1,301 | ||
| BetterHelp | 1,134 | 1,020 | 721 | ||
| Other | 0 | 13 | 11 | 25 | |
| Access Fees Revenue | 847 | 463 | |||
| Visit Fee Revenue | 222 | 90 | |||
| Total | 2,602 | 2,407 | 2,033 | 1,094 | 553 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Integrated Care | 192 | 135 | |||
| BetterHelp | 136 | 114 | |||
| Goodwill impairment | 0 | -13,403 | |||
| Other | 0 | -3 | |||
| Depreciation of property and equipment | -11 | -11 | |||
| Restructuring costs | -17 | -7 | |||
| Acquisition, integration, and transformation costs | -21 | -16 | |||
| Stock-based compensation | -202 | -218 | |||
| Amortization of intangible assets | -326 | -245 | |||
| Total | -249 | -13,653 |
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/23/2025 | 10.0% | 1.6% | -19.1% |
| 7/29/2025 | -1.7% | -7.6% | 2.8% |
| 2/26/2025 | -13.6% | -17.8% | -22.1% |
| 10/30/2024 | 1.6% | 6.5% | 35.2% |
| 7/31/2024 | -8.9% | -24.1% | -24.7% |
| 2/20/2024 | -23.7% | -26.0% | -24.8% |
| 10/24/2023 | -3.9% | -8.7% | -5.9% |
| 7/25/2023 | 27.0% | 21.8% | 1.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 7 |
| # Negative | 10 | 10 | 12 |
| Median Positive | 8.6% | 6.7% | 6.0% |
| Median Negative | -7.9% | -12.2% | -19.1% |
| Max Positive | 27.0% | 21.8% | 36.5% |
| Max Negative | -23.7% | -26.0% | -30.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10302025 | 10-Q 9/30/2025 |
| 6302025 | 7302025 | 10-Q 6/30/2025 |
| 3312025 | 5012025 | 10-Q 3/31/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 10312024 | 10-Q 9/30/2024 |
| 6302024 | 8012024 | 10-Q 6/30/2024 |
| 3312024 | 4262024 | 10-Q 3/31/2024 |
| 12312023 | 2232024 | 10-K 12/31/2023 |
| 9302023 | 10272023 | 10-Q 9/30/2023 |
| 6302023 | 7282023 | 10-Q 6/30/2023 |
| 3312023 | 5022023 | 10-Q 3/31/2023 |
| 12312022 | 3012023 | 10-K 12/31/2022 |
| 9302022 | 11022022 | 10-Q 9/30/2022 |
| 6302022 | 8032022 | 10-Q 6/30/2022 |
| 3312022 | 5022022 | 10-Q 3/31/2022 |
| 12312021 | 2282022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Paulus Kenneth H | 11172025 | Buy | 6.94 | 10,000 | 69,400 | 69,400 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |